AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02140710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic treatment
Description: visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
Study NCT03204058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral prophylaxis followed by placement of placebo gel
Study NCT03204058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Oral prophylaxis followed by placement of rosuvastatin gel
Study NCT03204058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral prophylaxis followed by placement of metformin gel
Study NCT02066896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lasertherapy
Description: Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
Study NCT02066896 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Lasertherapy
Description: Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
Study NCT01576718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.
Study NCT01576718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
Study NCT01576718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus
Description: Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
Study NCT01576718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT01576718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT01576718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT01186614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated CPR
Description: Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
Study NCT01186614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECMO
Description: Insertion of peripheral VA ECMO
Study NCT01186614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Coronary angiography and intervention where necessary will be performed following ECMO insertion
Study NCT01186614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
Study NCT02294539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg/amlodipine 5mg
Description: once daily, 1T, PO medication
Study NCT02294539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 100mg/amlodipine 5mg
Description: once daily, 1T, PO medication
Study NCT02294539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50mg/Hydrochlorothiazide 12.5mg
Description: once daily, 1T, PO medication
Study NCT02294539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100mg/Hydrochlorothiazide 25mg
Description: once daily, 1T, PO medication
Study NCT01126060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usage of Fibrin sealant
Description: Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
Study NCT01126060 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Thyroidectomy
Description: surgical removal of bilateral thyroid glands
Study NCT01126060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: surgical removal of bilateral thyroid glands
Study NCT04430413 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
Study NCT03612427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: S. Cholesterol S. Triglyceride
Description: S. Cholesterol S. Triglycerides
Study NCT00985621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 10 mg
Description: tanezumab 10 mg one dose at weeks 0 and 8
Study NCT00985621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 5 mg
Description: tanezumab 5 mg one dose at weeks 0 and 8
Study NCT00773058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: hydrocortisone 100mg q8h
Study NCT00773058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline 100ml q8h
Study NCT00985621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: oxycodone CR, 10-40 mg q12h
Study NCT00985621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00316589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
Study NCT01108484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise: Three 90-minutes sessions per week.
Study NCT01108484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet counseling
Description: Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
Study NCT01108484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet counseling + psycho-emotional support
Description: Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
Study NCT01554371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only
Study NCT01554371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02409121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information system
Description: Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
Study NCT05013866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair resin composite proximal
Description: Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
Study NCT05013866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair resin composite proximal
Description: Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
Study NCT04501133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation
Description: Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
Study NCT04501133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single pulse TMS
Description: Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
Study NCT02344537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Description: Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
Study NCT01031472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 formulation 1
Description: 100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
Study NCT01031472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 reference formulation
Description: GSK2248761 100mg Gelucire reference capsule with food
Study NCT01031472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 formulation 3
Description: 100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
Study NCT01031472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 formulation 2 or 4
Description: 100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
Study NCT03274154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Hyaluron 465 Innēov
Description: Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
Study NCT00416260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillation and Tracheal Gas Insufflation
Description: Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
Study NCT01633216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent OPV 2 week interval
Description: Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
Study NCT01633216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent OPV 4 week interval
Description: Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
Study NCT01633216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent OPV 2 week interval
Description: Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
Study NCT01633216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent OPV 4 week interval
Description: Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
Study NCT01633216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent OPV 4 week interval
Description: Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
Study NCT00402337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide acetate
Description: oral, once daily.
Study NCT00402337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: oral, once daily
Study NCT03555357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
Study NCT03555357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
Study NCT04133259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody
Description: Treatment of CHB patient with HLX10
Study NCT04133259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside/nucleotide analogues
Description: Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temsirolimus
Description: Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
Study NCT01946529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: Dosage and route of administration: 90 mg/m\^2/dose PO BID
Study NCT01946529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: If participant meets the criteria, they will have surgical resection of their tumor.
Study NCT01946529 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
Study NCT04963998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Wound Dressings with Copper Oxide
Description: Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
Study NCT01766323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
Study NCT01766323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
Study NCT05051683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer
Description: endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
Study NCT04758156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CleanViewAL
Description: 1L PEG + ascorbic acid bowel preparation for colonoscopy
Study NCT04758156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUPREP
Description: Oral sulfate solution for colonoscopy bowel preparation
Study NCT03904888 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: r-TAPP
Description: Robot-assisted repair
Study NCT03904888 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: l-TAPP
Description: Laporoscopic repair
Study NCT03904888 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: local anesthetics
Description: local anesthetics will be administred
Study NCT00611663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar® and Pneumo23®
Description: Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
Study NCT00611663 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Pneumo23®
Description: Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
Study NCT03909919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care or Usual Clinical Practice
Description: The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
Study NCT03909919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Care or Usual Clinical Practice
Description: The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
Study NCT01582633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012 trivalent influenza vaccine
Description: 2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose.
Study NCT01582633 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2012 trivalent influenza vaccine
Description: 2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose.
Study NCT04529252 — intervention group
Intervention type: OTHER
Intervention: Specimen collection
Description: Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
Study NCT03991169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight >43 kg.
Study NCT03973918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450mg QD 28 day cycle
Study NCT03973918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45mg BID 28 day cycle
Study NCT03973918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Research Bloods
Description: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
Study NCT03973918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Tissue
Description: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides